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b-Adrenergic Receptor Blockers in Hypertension
Sheldon W. Tobe, MD, MScCH (HPTE), FRCPC, FACP, FASH
Aboriginal and Rural Health Research, Northern Ontario School of Medicine, Division of Nephrology, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canadab-Blockers have been used widely since the 1970s in the
treatment of hypertension. In recent years, however, the use of
b-blockers as an initial therapy in the treatment of hyper-
tension has been challenged. The reasons for this controversy
and the rationale for keeping b-blockers as a recommended
treatment for hypertension are discussed in the articles in this
supplement to the Canadian Journal of Cardiology (CJC).
b-Blockers are efﬁcacious in the management of hyperten-
sion,1 but they are also known for their adverse effects on glucose
metabolism and insulin levels. Insulin resistance in hypertension
is associatedwith reduced skeletalmuscle bloodﬂow and reduced
insulin-mediated glucose utilization.2 Insulin resistance in
obesity is also caused in part by decreased muscle blood ﬂow and
reduced glucose utilization.3 Nonvasodilating b-blockers reduce
muscle bloodﬂowand impair insulin sensitivity.4Vasodilatingb-
blockers might counteract insulin resistance by increasingmuscle
blood ﬂow, thus restoring glucose utilization. Improved insulin
sensitivity was demonstrated for carvedilol in a comparison with
metoprolol5 and nebivolol compared with atenolol.6 These ef-
fects might be important from a hemodynamic perspective, as
described by Messerli and Grossman when they compared car-
vedilol with nonvasodilating b-blockers: “By shifting the hemo-
dynamic proﬁle froma pattern of normal cardiac output and high
vascular resistance to a pattern of low cardiac output and high
vascular resistance, traditional b-blockers make the hypertensive
patient hemodynamically older and may accelerate the biological
clock.”7 The vasodilating b-blockers might thus offer a potential
advantage in the management of hypertension.
The effect on central hemodynamics, as described by
Messerli and Grossman7 for nonvasodilating b-blockers,
would be expected to lead to a lack of effect on central blood
pressure, particularly in older patients. Lack of improvement
in central blood pressure is theorized to be at least in part
responsible for the higher risk of stroke found in outcome
trials with b-blockers compared with other antihypertensive
agents in older patients.8 As is pointed out in many of the
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Ob-blockers in hypertension has been debated hotly since the
publication of a meta-analysis on the subject by Lindholm
et al. in 2005.8 After this publication, b-blockers were rele-
gated to fourth-line therapy by the National Institute for
Health and Clinical Excellence on the management of
hypertension from the United Kingdom,9 and maintained
only as a possible choice for antihypertensive treatment by the
European Society of Hypertension,10 and the Eighth Joint
National Committee for hypertension in the United States.11
Having chaired the Canadian Hypertension Education Pro-
gram (CHEP) guidelines process for 5 years until 2012, I
personally believed that there was a need to explain why
Canadian hypertension guidelines continue to recommend
b-blockers for the initial management of hypertension in
patients younger than the age of 60 years, and as part of
combination therapy in hypertensive patients who require
more than 1 agent. The release in Canada of nebivolol, a new
vasodilatory b-blocker, provided the stimulus to review the
b-blocker class in antihypertensive therapy. For this supple-
ment of the CJC, volunteer experts and participants in
Canadian clinical practice guidelines groups, such as CHEP,
were invited to write targeted review articles to inform
clinicians managing hypertension in understanding how to
use this class of antihypertensive agent conﬁdently and safely.
Dr Pierre Larochelle, who is the immediate past President of
Hypertension Canada, together with his colleagues review 30
years ofb-blocker clinical trials for hypertension, startingwith the
seminal b-blocker studies and concluding with a description of
themajormeta-analyses of the hypertension literature.12DrRoss
Feldman, past Chair of CHEP and the ﬁrst President of Hy-
pertension Canada, has summarized the physiology and patho-
physiology ofb-blockers, including data fromhis own research.13
Dr Luc Poirier, who is presently Chair of the CHEP, provides a
clinical pharmacologist’s review of the mechanism and actions of
b-blockers and the heterogeneity within the class.14 In addition
to variability in their durations of action, the various b-blockers
have different properties. These properties affect how theywill be
used by clinicians managing patients with different conditions,
including ischemic heart disease, heart failure, and hypertension.
These properties include water or lipid solubility, the potency
and selectivity of blockade of the b1 receptor, and other b
receptors, the ability of the molecule to stimulate b-adrenergic
receptors (intrinsic sympathomimetic activity) and vasodilatory
activity (a table showing the properties of the commonly used
b-blockers is presented in the article by Larochelle et al.12).pen access under CC BY-NC-ND license.
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guidelines, reviews nebivolol and the literature describing its use
in hypertension and in heart disease.15 The article byDrs Kuyper
andKhan16 updates a previousmeta-analysis performed byKhan
andMcAlister from2006,17whichmotivated theCHEPposition
on recommending b-blockers as initial therapy for hypertension
therapy in patients younger than 60 years of age, in response to
themeta-analysis byLindholm et al. a year earlier.8 Their updated
meta-analysis was carried out to determine if the efﬁcacy of b-
blockers in hypertension could be stratiﬁed according to atenolol
vs nonatenolol agents in patients younger than the age of 60 and
in older patients. The role of b-blockers in atrial ﬁbrillation and
heart failure is discussed by Drs Paul Dorian and Paul Angaran,
who review the role of b-blockers in atrial ﬁbrillation, in the
context of comorbidities, including hypertension.18 The article
byRichards andTobe describes howb-blockers can be combined
with other antihypertensives to achieve synergy.19 Dr Luc Tru-
deau clearly summarizes the literature on central blood pressure
using data from beta blocker studies to illustrate the principles.20
b-Blockers remain part of our armamentarium for the man-
agement of hypertension. The vasodilating b-blockers have a
theoretical advantage over the nonvasodilating b-blockers. By
preservingmuscle blood ﬂow, they should improve the surrogate
outcomes of insulin resistance and central blood pres-
sure. Unfortunately, clinical outcome studies of vasodilating
b-blockers compared with other antihypertensive agents and
with the nonvasodilating b-blockers in the management of hy-
pertension are lacking. Because of this lack of evidence, vaso-
dilating b-blockers are not mentioned speciﬁcally as a subclass
in the CHEP hypertension recommendations. The theoretical
advantages of vasodilating b-blockers should motivate the orga-
nization of prospective clinical trials to determinewhether the use
of vasodilating b-blockers is associated with hard outcome dif-
ferences compared with nonvasodilating b-receptor antagonists.Funding Sources
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